

## belantamab mafodotin powder for concentrate for solution for infusion (Blenrep®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2727	<p>in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p> <p>SMC restriction: Patients with relapsed or refractory multiple myeloma eligible for second line treatment for whom lenalidomide is an unsuitable treatment option.</p>	Not routinely available as the ADTC is waiting for further advice from local clinical experts	13/10/2025	
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9475/belantamab-mafodotin-blenrep-smc2727-final-sept-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9475/belantamab-mafodotin-blenrep-smc2727-final-sept-2025-for-website.pdf</a>				

## belantamab mafodotin powder for concentrate for solution for infusion (Blenrep®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2747	in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy including lenalidomide.	Not routinely available as not recommended for use in NHS Scotland	13/10/2025	17/09/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9476/belantamab-mafodotin-blenrep-smc2747-final-sept-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9476/belantamab-mafodotin-blenrep-smc2747-final-sept-2025-for-website.pdf</a>				

<b>durvalumab concentrate for solution for infusion (Imfinzi®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2797	in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: - durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) - durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).	Available in line with local or regional guidance	14/10/2025	18/03/2026
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9478/durvalumab-imfinzi-final-sept-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9478/durvalumab-imfinzi-final-sept-2025-for-website.pdf</a>				
<b>nusinersen solution for injection (Spinraza®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2805	for the treatment of 5q spinal muscular atrophy. SMC restriction: Patients with symptomatic type 2 or type 3 (later-onset) 5q spinal muscular atrophy.	Not routinely available as there is a local preference for alternative medicines	13/10/2025	21/01/2026
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9482/umar-nusinersen-spinraza-final-sept-2025-amended-290925-for-website.pdf">https://scottishmedicines.org.uk/media/9482/umar-nusinersen-spinraza-final-sept-2025-amended-290925-for-website.pdf</a>				

<b>capivasertib film-coated tablet (Truqap®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2823	in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.	Not routinely available as not recommended for use in NHS Scotland	13/10/2025	17/09/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9477/capivasertib-truqap-final-sept-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9477/capivasertib-truqap-final-sept-2025-for-website.pdf</a>				
<b>linzagolix film-coated tablets (Yselty®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2841	in adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.	Not routinely available as there is a local preference for alternative medicines	14/10/2025	17/12/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9480/linzagolix-choline-yselty-abb-final-sept-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9480/linzagolix-choline-yselty-abb-final-sept-2025-for-website.pdf</a>				

fruquintinib hard capsule (Fruzaqla®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2858	treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy.	Available in line with local or regional guidance	13/10/2025	18/03/2026
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9479/fruquintinib-fruzaqla-resub-final-sept-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9479/fruquintinib-fruzaqla-resub-final-sept-2025-for-website.pdf</a>				
nivolumab concentrate for solution for infusion (Opdivo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2874	in combination with platinum-based chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgical resection, for the treatment of adults with resectable (tumours ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements.	Not routinely available as not recommended for use in NHS Scotland	13/10/2025	17/09/2025
<b>Other Decision Specified :</b> Non-submission				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9481/nivolumab-opdivo-non-sub-final-september-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9481/nivolumab-opdivo-non-sub-final-september-2025-for-website.pdf</a>				